Avidity Partners Management
Avidity Partners Management reported 17 stocks worth $428M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (39.1%), CGON (22.4%) and ORKA (15.3%). Compared with Q2 2026, the fund added to ORKA and JBIO, trimmed DNTH, CGON and CATX and sold out of RGEN, DXCM and TEM.
Latest filing: what Avidity Partners Management did in Q3 2026
vs Q2 2026None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() DNTH Dianthus Therapeutics Inc | $167M | 39.1% | 1.9M | −205K (−10%) | 8 of 8 | |
| 2 | ![]() CGON CG Oncology Inc | $95.6M | 22.4% | 1.3M | −50K (−4%) | 8 of 8 | |
| 3 | ![]() ORKA Oruka Therapeutics Inc | $65.4M | 15.3% | 785K | +25K (+3%) | 8 of 8 | |
| 4 | ![]() JBIO Jade Biosciences Inc | $28.1M | 6.6% | 2M | +299K (+18%) | 6 of 8 | |
| 5 | ![]() ELVN Enliven Therapeutics Inc | $25.2M | 5.9% | 550K | No change | 7 of 8 | |
| 6 | ![]() CATX Perspective Therapeutics Inc | $16.7M | 3.9% | 6.1M | −232K (−4%) | 8 of 8 | |
| 7 | ![]() AKTS Aktis Oncology Inc | $9.4M | 2.2% | 484K | No change | 3 of 8 | |
| 8 | ![]() IMUX Immunic Inc | $6.2M | 1.5% | 670K | No change | 2 of 8 | |
| 9 | ![]() MOBI Mobia Med Inc | $3.1M | 0.7% | 325K | −474K (−59%) | 2 of 8 | |
| 10 | ![]() PVLA Palvella Therapeutics Inc NE | $2.8M | 0.6% | 20K | −50K (−71%) | 4 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() RGEN Repligen Corp | $10.6M | 78K |
TEVA PHARMACEUTICAL INDS LTD | $6.8M | 200K |
![]() DXCM Dexcom Inc | $6.7M | 100K |
![]() TEM Tempus AI Inc | $6.1M | 105K |
![]() MDT Medtronic PLC F | $5.5M | 70K |
🔒 Free account: see all 28.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() CGON CG Oncology Inc | Call | $60.3M | 850K | +850,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Avidity Partners Management 13F FAQ
What does Avidity Partners Management own?
Avidity Partners Management reported 17 stocks worth $428M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (39.1%), CGON (22.4%) and ORKA (15.3%). The table above lists every position in the filing (the top 10 without an account).
What did Avidity Partners Management buy and sell in Q3 2026?
Compared with Q2 2026: 0 new positions, 2 added to, 12 trimmed and 28 sold out. It sold all of RGEN, DXCM and TEM.
When will Avidity Partners Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Avidity Partners Management's portfolio worth?
The Q3 2026 filing reports $428M in US stocks ($488M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.














